We are delighted to announce our upcoming webinar on Thursday, September 14, 10:00 am ET.
From the beta-amyloid hypothesis to AI-driven discoveries of novel biomarkers and breakthrough drugs in Alzheimer’s Disease.
Alzheimer’s disease research has taken center stage in the world of drug discovery and clinical development. The convergence of causal AI, supercomputing power, and multi-omic human data is allowing us to begin to unravel the molecular circuity of this debilitating disease in order to discover the next generation of breakthrough drugs and predictive biomarkers.
Join our upcoming webinar featuring Dr. Rudolf Tanzi, pioneer and co-discoverer of all three early-onset familial Alzheimer’s disease genes, including the first Alzheimer’s gene related to the β-Amyloid precursor protein (APP), John Dwyer, President of Global Alzheimer’s Platform Foundation (GAP), and myself, as we discuss the latest discoveries and developments in Alzheimer’s disease research, explore the pivotal role of the Bio-Hermes dataset in facilitating diverse and effective clinical trials, and engage in a discussion on how Digital Twins are revolutionizing the discovery novel biomarkers for clinical trial design and the next generation of breakthrough AD drugs.
Given the widespread impact of Alzheimer’s on individuals and families worldwide, with over 1,000 new cases being identified each day, the need to find solutions has never been more pressing.
This panel will discuss:
- Discovery of genetic drivers of Alzheimer’s Disease: Limitation and new frontiers
- Bio-Hermes dataset to enable diverse and effective clinical trials
- Digital Twins to drive the discovery of novel biomarkers for clinical trial design and the next generation of breakthrough AD drugs
Reserve you seat here.